Back to the Top 100
Paige logo

Rank 27AI & Clinical Intelligence

Paige

Develops AI-native diagnostic software and digital pathology tools to assist pathologists in detecting and treating cancer.

Visit website
Signal Score
90.1
Total raised
$220M
Stage
Series C
Founded
2017
Headquarters
New York, United States
Region
North America

Their signal

As the first company to receive FDA approval for AI pathology, Paige remains at the absolute forefront of digital diagnostic oncology.

Signal Score 90.1editorial estimate, see how it is built
Capital (25% weight)92

Total raised, quality of investors and recency of the last round.

Growth (25% weight)88

Revenue trajectory, customer count, hiring and market pull.

Clinical & regulatory (20% weight)93

Peer-reviewed evidence, FDA/CE clearances and live health-system deployments.

Team (15% weight)90

Founder track record, clinical depth on the bench and technical leadership.

Online visibility (15% weight)87

Search presence, press coverage, founder and brand reach, and how often the company shows up where buyers look.

Also in AI & Clinical Intelligence

Figures are subjective research desk estimates compiled from public sources and refreshed daily, published as editorial commentary. Company marks are shown for identification only and imply no endorsement or affiliation. Want a correction, an update or removal? and see our corrections and removals policy.